109 related articles for article (PubMed ID: 15469860)
1. Alteration of autoantibodies against p53 in Taiwanese lung cancer patients undergoing chemotherapy.
Lee YL; Shih CM; Chiou HL; Shiau MY; Chang GC; Chang YH
Clin Chim Acta; 2004 Nov; 349(1-2):87-96. PubMed ID: 15469860
[TBL] [Abstract][Full Text] [Related]
2. Autoantibodies against P53 protein in patients with transitional cell carcinoma of the bladder.
Sanchez-Carbayo M; Chulia MT; Niveiro M; Aranda I; Mira A; Soria F
Anticancer Res; 1999; 19(4C):3531-7. PubMed ID: 10629648
[TBL] [Abstract][Full Text] [Related]
3. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients.
Yu DH; Li JH; Wang YC; Xu JG; Pan PT; Wang L
Clin Chim Acta; 2011 May; 412(11-12):930-5. PubMed ID: 21277290
[TBL] [Abstract][Full Text] [Related]
4. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients.
Lai CL; Tsai CM; Tsai TT; Kuo BI; Chang KT; Fu HT; Perng RP; Chen JY
Clin Cancer Res; 1998 Dec; 4(12):3025-30. PubMed ID: 9865916
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of serum p53 antibodies in squamous cell carcinoma of the lung.
Komiya T; Hirashima T; Takada M; Masuda N; Yasumitsu T; Nakagawa K; Hosono Y; Kikui M; Tsuji S; Fukuoka M; Kawase I
Anticancer Res; 1997; 17(5B):3721-4. PubMed ID: 9427768
[TBL] [Abstract][Full Text] [Related]
6. Monitoring of p53 autoantibodies in lung cancer during therapy: relationship to response to treatment.
Zalcman G; Schlichtholz B; Trédaniel J; Urban T; Lubin R; Dubois I; Milleron B; Hirsch A; Soussi T
Clin Cancer Res; 1998 Jun; 4(6):1359-66. PubMed ID: 9626451
[TBL] [Abstract][Full Text] [Related]
7. The detection of quantitative serum p53 protein in lung cancer.
Sen E; Gönüllü U; Akar N
Tuberk Toraks; 2005; 53(3):231-7. PubMed ID: 16258881
[TBL] [Abstract][Full Text] [Related]
8. Circulating p53 antibodies as early markers of oral cancer: correlation with p53 alterations.
Ralhan R; Nath N; Agarwal S; Mathur M; Wasylyk B; Shukla NK
Clin Cancer Res; 1998 Sep; 4(9):2147-52. PubMed ID: 9748133
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies against tumour suppressor protein p53 in pleural effusions of patients with tuberculosis pleurisy.
Wang L; Chang YH; Lee YL; Shih CM; Hsu YT; Shen GH; Haung ML; Shiau MY
Ann Clin Biochem; 2007 Jan; 44(Pt 1):57-62. PubMed ID: 17270093
[TBL] [Abstract][Full Text] [Related]
10. A highly sensitive particle agglutination assay for the detection of P53 autoantibodies in patients with lung cancer.
Agaylan A; Binder D; Sauer M; Neuweiler H; Meyer O; Kiesewetter H; Salama A
Cancer; 2007 Dec; 110(11):2502-6. PubMed ID: 17932907
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.
Gadelhak NA; Gadelhak SA; El-Morsi DA; Abdelaziz MM; Abbas AT; El-Emshaty HM
Hepatogastroenterology; 2009; 56(94-95):1417-24. PubMed ID: 19950803
[TBL] [Abstract][Full Text] [Related]
12. P53 auto-antibodies in non-small cell lung cancer patients can predict increased life expectancy after radiotherapy.
Bergqvist M; Brattström D; Larsson A; Holmertz J; Hesselius P; Rosenberg L; Wagenius G; Brodin O
Anticancer Res; 1998; 18(3B):1999-2002. PubMed ID: 9677456
[TBL] [Abstract][Full Text] [Related]
13. Serum anti-p53 autoantibodies from patients with idiopathic pulmonary fibrosis associated with lung cancer.
Oshikawa K; Sugiyama Y
Respir Med; 2000 Nov; 94(11):1085-91. PubMed ID: 11127496
[TBL] [Abstract][Full Text] [Related]
14. Serum p53 antibodies: predictors of survival in small-cell lung cancer?
Murray PV; Soussi T; O'Brien ME; Smith IE; Brossault S; Norton A; Ashley S; Tavassoli M
Br J Cancer; 2000 Dec; 83(11):1418-24. PubMed ID: 11076647
[TBL] [Abstract][Full Text] [Related]
15. Expression of the p53 family in lung cancer.
Uramoto H; Sugio K; Oyama T; Nakata S; Ono K; Nozoe T; Yasumoto K
Anticancer Res; 2006; 26(3A):1785-90. PubMed ID: 16827107
[TBL] [Abstract][Full Text] [Related]
16. Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation.
Leffers N; Lambeck AJ; de Graeff P; Bijlsma AY; Daemen T; van der Zee AG; Nijman HW
Gynecol Oncol; 2008 Sep; 110(3):365-73. PubMed ID: 18571704
[TBL] [Abstract][Full Text] [Related]
17. p53 autoantibodies can be indicative of the development of breast cancer relapse.
Regele S; Vogl FD; Kohler T; Kreienberg R; Runnebaum IB
Anticancer Res; 2003; 23(1B):761-4. PubMed ID: 12680180
[TBL] [Abstract][Full Text] [Related]
18. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.
Antonia SJ; Mirza N; Fricke I; Chiappori A; Thompson P; Williams N; Bepler G; Simon G; Janssen W; Lee JH; Menander K; Chada S; Gabrilovich DI
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):878-87. PubMed ID: 16467102
[TBL] [Abstract][Full Text] [Related]
19. Serum anti-p53 antibodies as a diagnostic tumor marker: observations in patients with malignant and premalignant oral cavity lesions.
Porrini R; Vercellino V; Rocchetti V; Renò F; Giorda E; Pomato E; Cannas M; Sabbatini M
Minerva Stomatol; 2010 May; 59(5):233-9, 239-43. PubMed ID: 20502428
[TBL] [Abstract][Full Text] [Related]
20. Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer.
Marx D; Frey M; Zentgraf H; Adelssen G; Schauer A; Kuhn W; Meden H
Cancer Detect Prev; 2001; 25(2):117-22. PubMed ID: 11341346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
